BioSpace News Archive

On the tailcoat of Tuesday’s United Nations General Assembly, President Biden is hosting a virtual COVID-19 summit Wednesday, calling for the end of the pandemic globally.

Triumvira’s inaugural program is directed against HER2, a well-known tumor-associated antigen that is expressed in multiple tumors.

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare disorders, announced the completion of enrollment in DESTINY-1 Efficacy and Safety Trial In NASH), a dose-ranging Phase 2 trial evaluating PXL065 for the treatment of NASH.

The global healthcare additive manufacturing market is growing due to the rising demand for personalized medical devices, such as implants, and the advent of sophisticated technology to manufacture a variety of products with complex and simple designs.

Gingivostomatitis is a contagious mouth infection that causes blisters, painful sores, and swelling in the tongue and uvula. It usually spreads via saliva of an infected individual or by direct contact with a lesion or sore.

BioMed Realty owns and operates 14 million square feet of mission-critical lab office space throughout the US and UK – helping 250+ clients discover and advance the next generation of medicines and therapies.

Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, announced an agreement to enhance its go-to-market capabilities with Ashfield Healthcare, LLC, part of UDG Healthcare.

MiroBio, a biotechnology company advancing a new class of precision therapies designed to address the immune imbalance that drives autoimmune disease, announced the appointment of Carolin Barth, M.D., as chief executive officer.

Sage Therapeutics, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced the appointment of Chris Benecchi as Chief Commercial Officer.

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021, Vicente Anido, PhD. no longer serves as the Company’s Chairman and Chief Executive Officer or as a director of the Company.